2021.10.26 Clovis Oncology (CLVS)_1st visit, PARP 억제제, 표적항암제

2021.10.26 $4.39 거의 최저점 근처에 와 있는 상황 아래 링크는 CLVS의 최근 회사소개 자료 September 21, 2021 Clovis Oncology Corporate Presentation 주력 파이프라인 Rucaparib이라는 PARP 억제제가 FDA 승인되어, 시판 중임 Rucaparib, an oral, small molecule inhibitor of poly (ADP-ribose) polymerase (PARP) 1, 2 and 3 is being developed in multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. Clovis holds global rights for rucaparib. 임상 1상에 있는 3B Pharmaceuticals로부..........

원문링크 : 2021.10.26 Clovis Oncology (CLVS)_1st visit, PARP 억제제, 표적항암제